<DOC>
	<DOC>NCT00129545</DOC>
	<brief_summary>This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm. This study was amended to allow for a non-randomized arm and increased enrollment.</brief_summary>
	<brief_title>WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation</brief_title>
	<detailed_description>The WATCHMAN device is designed to be permanently implanted distal to the ostium of the left atrial appendage (LAA) to trap potential emboli before they exit the LAA.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patient has paroxysmal, persistent or permanent nonvalvular atrial fibrillation (AF) Eligible for long term warfarin CHADS score &gt;= 1 [congestive heart failure (CHF), history of high blood pressure, 75 years of age or older, diabetes, prior stroke or transient ischemic attack (TIA)] Contraindicated for warfarin Contraindicated for aspirin or clopidogrel (Plavix) Congestive heart failure (CHF) Class 4 Implanted mechanical valve Atrial septal or Patent Foramen Ovale (PFO) device Platelets &lt; 100,000 or hemoglobin &lt; 10 Left ventricular ejection fraction (LVEF) &lt; 30%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>AF</keyword>
	<keyword>A Fib</keyword>
	<keyword>Stroke</keyword>
	<keyword>Coumadin</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Blood thinning medication</keyword>
	<keyword>transient ischemic attack (TIA)</keyword>
	<keyword>WATCHMAN</keyword>
	<keyword>Left atrial appendage</keyword>
	<keyword>LAA isolation</keyword>
	<keyword>LAA occlusion</keyword>
</DOC>